Paola Queirolo

List of Publications by Year
in descending order

179	11,886	38742 50	30087 103
papers	citations	h-index	g-index

192	192	192	14219
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 213-221.	2.4	8
2	Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110662.	3.2	9
3	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Cancers, 2022, 14, 377.	3.7	17
4	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. Journal of Translational Medicine, 2022, 20, 159.	4.4	12
5	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. European Journal of Cancer, 2022, 166, 202-207.	2.8	4
6	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. Journal of Clinical Oncology, 2022, 40, 9522-9522.	1.6	37
7	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. European Journal of Cancer, 2022, 171, 183-192.	2.8	4
8	Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup. ESMO Open, 2022, 7, 100525.	4.5	10
9	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 157, 103187.	4.4	17
10	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81
11	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews, 2021, 92, 102133.	7.7	4
12	Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature. Cancer Investigation, 2021, 39, 9-14.	1.3	12
13	Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and metaâ€analysis. Molecular Carcinogenesis, 2021, 60, 167-171.	2.7	5
14	The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. BMC Cancer, 2021, 21, 8.	2.6	2
15	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
16	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers, 2021, 13, 475.	3.7	20
17	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. Journal of Translational Medicine, 2021, 19, 70.	4.4	5
18	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	7.0	44

#	Article	IF	Citations
19	Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. Cancers, 2021, 13, 2440.	3.7	6
20	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	10.7	224
21	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	4.4	14
22	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	2.8	7
23	Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 733917.	2.8	19
24	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. Frontiers in Oncology, 2021, 11, 739006.	2.8	12
25	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Annals of Oncology, 2021, 32, S1314-S1315.	1.2	21
26	Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. ESMO Open, 2021, 6, 100251.	4.5	39
27	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. European Journal of Cancer, 2021, 157, 250-258.	2.8	52
28	Systemic Treatment in Advanced Melanoma. Updates in Surgery Series, 2021, , 167-174.	0.1	0
29	New Melanoma Staging: Prognostic Factors. Updates in Surgery Series, 2021, , 47-53.	0.1	0
30	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	2.8	2
31	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. Journal of Clinical Medicine, 2021, 10, 5475.	2.4	8
32	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ, The, 2021, 375, e066381.	6.0	53
33	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. Journal of Medical Genetics, 2020, 57, 316-321.	3.2	33
34	HOâ€1 downregulation favors BRAF V600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition. International Journal of Cancer, 2020, 146, 1950-1962.	5.1	19
35	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology, 2020, 47, 302-304.	2.2	15
36	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097700.	3.2	6

#	Article	IF	Citations
37	Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient. Frontiers in Immunology, 2020, 11, 579523.	4.8	10
38	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Nonâ€“Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	2.9	4
39	Skin signs resembling vascular acrosyndromes during the COVIDâ€19 outbreak in Italy. Clinical and Experimental Dermatology, 2020, 45, 757-758.	1.3	23
40	Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. Cancers, 2020, 12, 1468.	3.7	14
41	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. Cancer Immunology, Immunotherapy, 2020, 69, 653-662.	4.2	16
42	Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients. Journal of Translational Medicine, 2020, 18, 78.	4.4	17
43	Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. Clinical Immunology, 2020, 215, 108428.	3.2	15
44	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. Cancers, 2020, 12, 1007.	3.7	19
45	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
46	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. Expert Review of Anticancer Therapy, 2020, 20, 403-413.	2.4	2
47	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
48	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
49	Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.. Journal of Clinical Oncology, 2020, 38, 10023-10023.	1.6	7
50	Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.. Journal of Clinical Oncology, 2020, 38, e21114-e21114.	1.6	6
51	A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).. Journal of Clinical Oncology, 2020, 38, TPS10081-TPS10081.	1.6	2
52	New insights in melanoma biology: Running fast towards precision medicine. Seminars in Cancer Biology, 2019, 59, 161-164.	9.6	2
53	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
54	The adjuvant treatment revolution for high-risk melanoma patients. Seminars in Cancer Biology, 2019, 59, 283-289.	9.6	40

#	Article	IF	Citations
55	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine, 2019, 25, 941-946.	30.7	256
56	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advancedNRAS- orBRAF-mutated melanoma. Oncotarget, 2019, 10, 1850-1859.	1.8	16
57	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019, 107, 175-185.	2.8	13
58	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunology, Immunotherapy, 2019, 68, 97-107.	4.2	61
59	CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. Journal of the American Academy of Dermatology, 2019, 80, 1263-1271.	1.2	16
60	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	10.7	183
61	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	7.7	31
62	Effect of Age on Melanoma Risk, Prognosis and Treatment Response. Acta Dermato-Venereologica, 2018, 98, 624-629.	1.3	52
63	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget, 2018, 9, 12408-12417.	1.8	11
64	Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations. Oncotarget, 2018, 9, 5691-5702.	1.8	9
65	Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget, 2018, 9, 12452-12470.	1.8	73
66	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 435-445.	10.7	399
67	Identification, genetic testing, and management of hereditary melanoma. Cancer and Metastasis Reviews, 2017, 36, 77-90.	5.9	93
68	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	2.8	31
69	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Annals of Oncology, 2017, 28, 1380-1387.	1.2	134
70	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. Cancer and Metastasis Reviews, 2017, 36, 35-42.	5.9	35
71	Binimetinib for the treatment of NRAS-mutant melanoma. Expert Review of Anticancer Therapy, 2017, 17, 985-990.	2.4	21
72	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	27.0	1,752

#	Article	IF	Citations
73	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology, 2017, 8, 386.	4.8	27
74	Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. Oncotarget, 2017, 8, 8069-8082.	1.8	34
75	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714.	1.8	29
76	Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Human Genetics, 2016, 135, 1241-1249.	3.8	24
77	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. Journal of Investigative Dermatology, 2016, 136, 1917-1920.	0.7	13
78	The <scp>CDKN</scp>2A/p16<scp>^{INK}</scp>^{4a} 5â€²<scp>UTR</scp> sequence and translational regulation: impact of novel variants predisposing to melanoma. Pigment Cell and Melanoma Research, 2016, 29, 210-221.	3.3	9
79	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Annals of Oncology, 2016, 27, 732-738.	1.2	321
80	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332.	1.2	32
81	Update on Metastatic Uveal Melanoma: Progress and Challenges. BioDrugs, 2016, 30, 161-172.	4.6	14
82	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. Cancer Treatment Reviews, 2016, 45, 38-45.	7.7	71
83	Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. Oncotarget, 2016, 7, 60858-60871.	1.8	14
84	Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma. JAMA Ophthalmology, 2015, 133, 1013.	2.5	48
85	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of Oncology, 2015, 26, 798-803.	1.2	118
86	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. OncoTargets and Therapy, 2015, 8, 157.	2.0	134
87	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treatment Reviews, 2015, 41, 519-526.	7.7	63
88	Vemurafenib inBRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	2.4	6
89	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. Cancer Investigation, 2014, 32, 144-149.	1.3	90
90	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. British Journal of Cancer, 2014, 110, 1721-1726.	6.4	53

#	Article	IF	Citations
91	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. Journal of Chemotherapy, 2014, 26, 193-201.	1.5	17
92	Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent. Journal of Surgical Oncology, 2014, 109, 270-274.	1.7	51
93	The treatment of melanoma brain metastases before the advent of targeted therapies. Melanoma Research, 2014, 24, 61-67.	1.2	22
94	<scp>ADAM</scp>10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell and Melanoma Research, 2014, 27, 1138-1148.	3.3	25
95	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. Journal of Neuro-Oncology, 2014, 118, 109-116.	2.9	103
96	Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nature Genetics, 2014, 46, 482-486.	21.4	283
97	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 675-683.	4.2	230
98	Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Archives of Dermatological Research, 2014, 306, 521-526.	1.9	31
99	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental and Clinical Cancer Research, 2014, 33, 30.	8.6	97
100	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	4.4	149
101	Discrepant alterations in main candidate genes among multiple primary melanomas. Journal of Translational Medicine, 2014, 12, 117.	4.4	24
102	A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: Potential applications in autoimmunity and cancer. Human Immunology, 2014, 75, 730-739.	2.4	7
103	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	10.7	242
104	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	2.8	149
105	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget, 2014, 5, 10206-10221.	1.8	104
106	The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-Î± production. Journal of Translational Medicine, 2013, 11, 108.	4.4	136
107	Prevalence of the <scp>E</scp>318<scp>K MITF</scp> germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell and Melanoma Research, 2013, 26, 259-262.	3.3	80
108	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, The, 2013, 14, 249-256.	10.7	587

#	Article	IF	Citations
109	Treatment of metastatic uveal melanoma with intravenous fotemustine. Melanoma Research, 2013, 23, 196-198.	1.2	30
110	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Annals of Oncology, 2013, 24, 2911-2915.	1.2	119
111	Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. Cancer Investigation, 2013, 31, 336-345.	1.3	55
112	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	2.1	4
113	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Journal of Experimental and Clinical Cancer Research, 2013, 32, 82.	8.6	23
114	Open-label, multicenter safety study of vemurafenib in patients with BRAF^{V600} mutationâ€“positive metastatic melanoma.. Journal of Clinical Oncology, 2013, 31, 9046-9046.	1.6	3
115	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9070-9070.	1.6	9
116	Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity. Cancer Research, 2012, 72, 1407-1415.	0.9	267
117	Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell and Melanoma Research, 2012, 25, 384-394.	3.3	61
118	CDKN2Ais the main susceptibility gene in Italian pancreatic cancer families. Journal of Medical Genetics, 2012, 49, 164-170.	3.2	64
119	Uveal melanoma. Cancer Treatment Reviews, 2012, 38, 549-553.	7.7	120
120	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncology, The, 2012, 13, 879-886.	10.7	273
121	The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental and Clinical Cancer Research, 2012, 31, 91.	8.6	25
122	Mda-9/Syntenin Is Expressed in Uveal Melanoma and Correlates with Metastatic Progression. PLoS ONE, 2012, 7, e29989.	2.5	64
123	Melanoma cells become resistant to <scp>NK</scp>â€cellâ€mediated killing when exposed to <scp>NK</scp>â€cell numbers compatible with <scp>NK</scp>â€cell infiltration in the tumor. European Journal of Immunology, 2012, 42, 1833-1842.	2.9	94
124	Upcoming strategies for the treatment of metastatic melanoma. Archives of Dermatological Research, 2012, 304, 177-184.	1.9	44
125	<scp>MC</scp>1R variation and melanoma risk in relation to host/clinical and environmental factors in <scp>CDKN</scp>2A positive and negative melanoma patients. Experimental Dermatology, 2012, 21, 718-720.	2.9	33
126	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy, 2012, 61, 41-48.	4.2	118

#	Article	IF	Citations
127	Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.. Journal of Clinical Oncology, 2012, 30, 8513-8513.	1.6	5
128	The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.. Journal of Clinical Oncology, 2012, 30, 8529-8529.	1.6	7
129	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. Journal of Clinical Oncology, 2012, 30, 8573-8573.	1.6	13
130	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. Journal of the National Cancer Institute, 2011, 103, 1529-1539.	6.3	27
131	Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy.. Journal of Clinical Oncology, 2011, 29, 8588-8588.	1.6	2
132	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research, 2010, 16, 5862-5872.	7.0	56
133	Functional analysis of CDKN2A/p16INK4a 5â€²-UTR variants predisposing to melanoma. Human Molecular Genetics, 2010, 19, 1479-1491.	2.9	51
134	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology, 2010, 21, 1712-1717.	1.2	468
135	Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20847-20852.	7.1	264
136	Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. International Immunology, 2009, 21, 793-801.	4.0	134
137	Clinical genetic testing for familial melanoma in Italy: A cooperative study. Journal of the American Academy of Dermatology, 2009, 61, 775-782.	1.2	45
138	9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. European Journal of Cancer, Supplement, 2009, 7, 581.	2.2	3
139	CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Research, 2009, 19, 142-145.	1.2	20
140	Predictive role of preoperative lymphoscintigraphy on the status of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma. Melanoma Research, 2009, 19, 243-251.	1.2	4
141	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. PLoS ONE, 2009, 4, e8132.	2.5	36
142	CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell and Melanoma Research, 2008, 21, 700-709.	3.3	46
143	Medical treatment of uveal melanoma. Tumori, 2007, 93, suppl 27-30.	1.1	1
144	Targeted therapies in melanoma. Cancer Treatment Reviews, 2006, 32, 524-531.	7.7	20

#	Article	IF	Citations
145	Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-Î±2b in metastatic melanoma. Annals of Oncology, 2006, 17, 571-577.	1.2	101
146	Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Human Molecular Genetics, 2006, 15, 2682-2689.	2.9	41
147	Update: current management issues in malignant melanoma. Melanoma Research, 2005, 15, 319-324.	1.2	13
148	Biochemotherapy in metastatic melanoma: quo vadis?. Melanoma Research, 2005, 15, 471-473.	1.2	2
149	The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group. European Journal of Surgical Oncology, 2005, 31, 1191-1197.	1.0	17
150	INK4/ARF germline alterations in pancreatic cancer patients. Annals of Oncology, 2004, 15, 70-78.	1.2	45
151	Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review. Journal of Surgical Oncology, 2004, 85, 133-140.	1.7	23
152	Sentinel lymph node biopsy in melanoma patients: the medical oncologist's perspective. Journal of Surgical Oncology, 2004, 85, 162-165.	1.7	5
153	Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Research, 2004, 14, 443-448.	1.2	26
154	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Journal of Clinical Oncology, 2002, 20, 4169-4180.	1.6	361
155	High prevalence of the G101W germline mutation in theCDKN2A(P16ink4a) gene in 62 Italian malignant melanoma families. American Journal of Medical Genetics Part A, 2002, 107, 214-221.	2.4	60
156	A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma. Tumori, 2001, 87, 219-222.	1.1	11
157	Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy. Oncology, 2001, 60, 88-93.	1.9	9
158	Selective lymph node dissection in patients with intermediate thickness melanoma: our experience. Anticancer Research, 2000, 20, 497-500.	1.1	3
159	Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial. Annals of Surgical Oncology, 1999, 6, 272-278.	1.5	17
160	Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. , 1999, 83, 441-448.		78
161	Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon Î±2a and tamoxifen in metastatic melanoma. Melanoma Research, 1999, 9, 503-510.	1.2	17
162	Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer. Breast Cancer Research and Treatment, 1997, 42, 183-186.	2.5	10

#	Article	IF	Citations
163	Analysis of the proliferative and phenotypic properties of tumor infiltrating lymphocytes expanded in vitro in the course of the clinical trial of adoptive immunotherapy of metastatic melanoma. Oncology Reports, 1997, 4, 27-31.	2.6	2
164	Merkel cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease: review of clinical cases. Anticancer Research, 1997, 17, 673-7.	1.1	17
165	Merkel cell carcinoma of the skin. Treatment of primary, recurrent and metastatic disease: review of clinical cases. Anticancer Research, 1997, 17, 2339-42.	1.1	7
166	Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology, 1996, 38, 487-494.	2.3	11
167	Radiation-associated angiosarcoma: Diagnostic and therapeutic implicationsâ€"Two case reports and a review of the literature. Cancer, 1996, 77, 2496-2502.	4.1	83
168	Randomized cooperative study of perioperative chemotherapy in breast cancer.. Journal of Clinical Oncology, 1995, 13, 2712-2721.	1.6	28
169	Computer graphics as a tool in cytogenetic research and eduation. Bioinformatics, 1995, 11, 463-468.	4.1	4
170	Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.. Journal of Clinical Oncology, 1994, 12, 806-811.	1.6	156
171	BREAST-CANCER IN THE ELDERLY - DETECTION AND TREATMENT MODALITIES IN 341 WOMEN. International Journal of Oncology, 1994, 5, 1399-403.	3.3	0
172	Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. British Journal of Cancer, 1994, 69, 385-391.	6.4	70
173	Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2. Melanoma Research, 1994, 4, 127-133.	1.2	7
174	High Dose Intensity Chemotherapy without Bone Marrow Support: Role of Granulocyte-Macrophage Colony-Stimulating Factor. Annals of the New York Academy of Sciences, 1993, 698, 389-397.	3.8	1
175	Impact of Irradiation of Residual Breast on Adjuvant Chemotherapy Dose Intensity. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 58-60.	1.3	6
176	Second-Line Hormonotherapy for Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 522-525.	1.3	9
177	Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. Annals of Oncology, 1992, 3, 165-166.	1.2	9
178	An outpatient phase I study of a subcutaneous interleukin-2 and intramuscular alpha-2a-interferon combination in advanced malignancies. Annals of Oncology, 1992, 3, 559-563.	1.2	10
179	Continuous Venous Infusion of Vinblastine in Metastatic Breast Cancer. Chemotherapy, 1991, 37, 146-149.	1.6	3